| Sequential delivery of cyclopeptide ra-v and doxorubicin for combination therapy on resistant tumor and in situ monitoring of cytochrome c release | |
| Chen, Huachao1; Wang, Yurong1; Yao, Yongrong1; Qiao, Shenglin2; Wang, Hao2; Tan, Ninghua1 | |
| 刊名 | Theranostics
 |
| 2017 | |
| 卷号 | 7期号:15页码:3781-3793 |
| 关键词 | Cancer Sequential drug delivery Combination therapy Cytochrome c Cyclopeptide ra-v Doxorubicin |
| ISSN号 | 1838-7640 |
| DOI | 10.7150/thno.20892 |
| 通讯作者 | Tan, ninghua(nhtan@cpu.edu.cn) |
| 英文摘要 | A programmed drug delivery system that can achieve sequential release of multiple therapeutics under different stimulus holds great promise to enhance the treatment efficacy and overcome multi-drug resistance (mdr) in tumor. herein, multi-organelle-targeted and ph/cytochrome c (cyt c) dual-responsive nanoparticles were designed for combination therapy on resistant tumor. in this system (designated dglipo nps), doxorubicin (dox) was intercalated into the dna duplex containing a cyt c aptamer, which subsequently loaded in the dendrigraftpoly-l-lysines (dgl) cores of dglipo nps, while cyclopeptide ra-v was doped into the ph-sensitive liposomal shells. after dual modification with c(rgdfk) and mitochondria-penetrating peptide (mpp), dglipo nps could successively deliver the two drugs into lysosome and mitochondria of cancer cells, and achieve sequential drug release in virtue of the unique characteristic of these two organelles. the organelle-specific and spatiotemporally controlled release of dox and ra-v led to enhanced therapeutic outcomes in mdr tumor. more significantly, the dglipo nps were successfully applied to monitor cyt c release during mitochondria-mediated apoptotic process. this work represents a versatile strategy for precise combination therapy against resistant tumor with spatiotemporal control, and provides a potential tool for cyt c-related apoptotic studies. |
| WOS关键词 | MESOPOROUS SILICA NANOPARTICLES ; OVERCOMING MULTIDRUG-RESISTANCE ; ENHANCED ANTITUMOR EFFICACY ; BREAST-CANCER CELLS ; DRUG-DELIVERY ; CISPLATIN ; ACTIVATION ; MITAPLATIN ; APOPTOSIS ; PRODRUG |
| WOS研究方向 | Research & Experimental Medicine |
| WOS类目 | Medicine, Research & Experimental |
| 语种 | 英语 |
| 出版者 | IVYSPRING INT PUBL |
| WOS记录号 | WOS:000408444200013 |
| 内容类型 | 期刊论文 |
| URI标识 | http://www.corc.org.cn/handle/1471x/2177021 |
| 专题 | 高能物理研究所 |
| 通讯作者 | Tan, Ninghua |
| 作者单位 | 1.China Pharmaceut Univ, State Key Lab Nat Med, Jiangsu Key Lab TCM Evaluat & Translat Res, Sch Tradit Chinese Pharm, Nanjing 211198, Jiangsu, Peoples R China 2.Natl Ctr Nanosci & Technol, CAS Key Lab Biol Effects Nanomat & Nanosafety, Beijing 100190, Peoples R China |
| 推荐引用方式 GB/T 7714 | Chen, Huachao,Wang, Yurong,Yao, Yongrong,et al. Sequential delivery of cyclopeptide ra-v and doxorubicin for combination therapy on resistant tumor and in situ monitoring of cytochrome c release[J]. Theranostics,2017,7(15):3781-3793. |
| APA | Chen, Huachao,Wang, Yurong,Yao, Yongrong,Qiao, Shenglin,Wang, Hao,&Tan, Ninghua.(2017).Sequential delivery of cyclopeptide ra-v and doxorubicin for combination therapy on resistant tumor and in situ monitoring of cytochrome c release.Theranostics,7(15),3781-3793. |
| MLA | Chen, Huachao,et al."Sequential delivery of cyclopeptide ra-v and doxorubicin for combination therapy on resistant tumor and in situ monitoring of cytochrome c release".Theranostics 7.15(2017):3781-3793. |
| 个性服务 |
| 查看访问统计 |
| 相关权益政策 |
| 暂无数据 |
| 收藏/分享 |
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。
修改评论